Description
PT-141 10mg is a synthetic cyclic heptapeptide studied for its interaction with MC3R and MC4R melanocortin receptors and downstream cAMP signaling activity in controlled laboratory environments.
Chemical Information
- Chemical Name: PT-141 (Bremelanotide; cyclo[Nle4, Asp5, D-Phe7]-alpha-MSH(4-11))
- Also Known As: Bremelanotide; PT141; melanotan II metabolite (related but distinct structure)
- Compound Class: Synthetic cyclic melanocortin receptor agonist; selective MC3R and MC4R agonist
- Molecular Formula: C50H68N14O10
- Molecular Weight: 1,025.2 g/mol
- CAS Number: 189691-06-3
- FDA Status: Approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder — research-grade compound is not equivalent to the approved pharmaceutical formulation
Applications
- MC3R and MC4R selective agonism studies in hypothalamic cell models. PT-141 provides CNS melanocortin receptor activation without the MC1R pigmentation confound that complicates interpretation in Melanotan II experiments; useful when the research question involves specifically hypothalamic melanocortin circuit biology
- Comparative melanocortin receptor subtype pharmacology. Systematic comparison of PT-141 (MC3R/MC4R) versus Melanotan II (MC1R-MC5R pan) using the same cAMP assay format characterizes receptor subtype contribution to observed signaling outcomes
- Melanocortin system/HPG axis intersection research. MC4R activation in the hypothalamus connects to the HPG axis through shared neuroendocrine circuits; PT-141’s MC3R/MC4R selectivity positions it as a tool for studying this intersection without melanocyte involvement
- POMC precursor peptide pharmacology research. PT-141 as a defined structural analog of the alpha-MSH active core enables structure-activity research within the POMC-derived peptide family examining how ring closure and amino acid substitution affect receptor selectivity profiles
- Hypothalamic autonomic output circuit research. MC4R in the paraventricular nucleus drives autonomic nervous system output; PT-141-mediated MC4R activation studies have been used to map the downstream autonomic circuit consequences of hypothalamic melanocortin receptor activation
Storage and Handling
Store lyophilized powder at -20C for long-term stability, or at 2-8C for short-term use. Protect from heat, moisture, and direct light. Reconstituted solutions should be stored at 2-8C and used promptly. Avoid repeated freeze-thaw cycles.
Compliance Notice
PT-141 is for laboratory research use only. They are not for human or veterinary use and carry no therapeutic, diagnostic, or clinical indication. Bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder. However, this research-grade compound is not equivalent to the approved pharmaceutical formulation. FDA has not evaluated this product. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.
